Tandem Diabetes Care, Inc. (TNDM) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

TransMedics Group, Inc.

AtriCure, Inc.

PROCEPT BioRobotics Corp.

Veracyte, Inc.

Integer Holdings Corp.

Tandem Diabetes Care, Inc.

Alphatec Holdings, Inc.

NovoCure Ltd.

InMode Ltd.

STAAR Surgical Co.

Pacific Biosciences of California, Inc.

Why is Tandem Diabetes Care, Inc. ?

Poor Management Efficiency with a low ROE of 0.30%

The company has been able to generate a Return on Equity (avg) of 0.30% signifying low profitability per unit of shareholders funds

Flat results in Dec 25

NET PROFIT(Q) At USD -0.59 MM has Fallen at -178.01%
DEBT-EQUITY RATIO (HY) Highest at 100.99 %
CASH AND EQV(HY) Lowest at USD 611.78 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 14.29%, its profits have fallen by -12.6%

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Tandem Diabetes Care, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Tandem Diabetes Care, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Tandem Diabetes Care, Inc.

21.31%

-0.60

91.35%

S&P 500

18.81%

0.98

19.26%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

15.26%

EBIT Growth (5y)

-255.93%

EBIT to Interest (avg)

-9.31

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.01

Sales to Capital Employed (avg)

1.62

Tax Ratio

5.41%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

2.83%

ROE (avg)

0.30%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

9.65

EV to EBIT

-17.23

EV to EBITDA

-21.48

EV to Capital Employed

7.81

EV to Sales

1.52

PEG Ratio

Dividend Yield

ROCE (Latest)

-45.34%

ROE (Latest)

-68.79%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Bearish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

No Trend

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company

NET PROFIT(HY)

Higher at USD -18.95 MM

RAW MATERIAL COST(Y)

Fallen by -3.58% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 3.37 times

NET SALES(Q)

Highest at USD 290.38 MM

OPERATING PROFIT(Q)

Highest at USD 12.79 MM

OPERATING PROFIT MARGIN(Q)

Highest at 4.4 %

PRE-TAX PROFIT(Q)

Highest at USD 4.68 MM

-6What is not working for the Company

NET PROFIT(Q)

At USD -0.59 MM has Fallen at -178.01%

DEBT-EQUITY RATIO (HY)

Highest at 100.99 %

CASH AND EQV(HY)

Lowest at USD 611.78 MM

Here's what is working for Tandem Diabetes Care, Inc.

Pre-Tax Profit

At USD 4.68 MM has Grown at 29,162.5%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Sales

Highest at USD 290.38 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Operating Profit

Highest at USD 12.79 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin

Highest at 4.4 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at USD 4.68 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Inventory Turnover Ratio

Highest at 3.37 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -3.58% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at USD 4.5 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Tandem Diabetes Care, Inc.

Net Profit

At USD -0.59 MM has Fallen at -178.01%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Debt-Equity Ratio

Highest at 100.99 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Cash and Eqv

Lowest at USD 611.78 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents